Clinical Trial Update: Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial combining pertuzumab with lenvatinib for locally advanced head and neck squamous cell carcinoma; enrollment is currently by invitation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Pertuzumab (pertuzumab)

Snippet

Sponsor: Zhejiang Provincial People's Hospital | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: ENROLLING_BY_INVITATION